Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B

Neurocrine Biosciences Inc. has completed its acquisition of Soleno Therapeutics Inc., strengthening its position in endocrinology and rare disease. The acquisition adds VYKAT XR (diazoxide choline) tablets, the first and only approved medicine for hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome, to Neurocrine’s first-in-class commercial portfolio alongside INGREZZA (valbenazine) and CRENESSITY (crinecerfont).

Neurocrine initially announced the transaction representing a total equity value of $2.9 billion on April 6, 2026.

“Today marks an important advancement in Neurocrine’s mission to deliver life-changing treatments for patients with significant unmet needs,” said Kyle W. Gano, Ph.D., CEO, Neurocrine Biosciences. “We welcome our Soleno colleagues to Neurocrine and share their deep commitment to the Prader-Willi syndrome community, and we look forward to working together to make VYKAT XR available to more patients and their families.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.